Drug Profile
BYK 324677
Alternative Names: BYK324677Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Nycomed
- Developer Takeda Pharmaceuticals International GmbH
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in Germany (PO, Capsule)
- 30 Mar 2012 Nycomed is now called Takeda Pharmaceuticals International GmbH
- 30 Nov 2011 Nycomed completes a phase I trial in Healthy volunteers in Germany (NCT01386541)